Creative Biolabs Released Antibody Glycoengineering Service

With the common efforts of its scientists, Creative Biolabs has successfully developed antibody
glycoengineering service for research, manufacturing and clinical development based on the
GlycoOpitimize™ platform.

Glycosylation is one of the most common post-translational modification mainly taking place in
the endoplasmic reticulum (ER) and Golgi apparatus. It has a major impact on the efficacy and
stability of biopharmaceuticals. Therefore, antibody glycoengineering is developed as a method to
control the composition of glycans and to enhance the pharmacological properties of therapeutic
antibodies, including physical stability, immunogenicity, pharmacokinetics and target recognition.

With modern recombination techniques, the genes of a set of specific glycosyltransferases or

glycosidases can be systematically knockoutockin or regulated to produce glycoengineered
antibodies with more humanized and homogeneous glycosylation, better pharmacokinetics and
enhanced pharmacological efficacy.

For instance, by removing the core fucose residue from the Fc region of the antibody, the affinity
of the antibody for receptors on immune effector cells will be increased. Besides, the capacity to
recruit immune cells such as macrophages/monocytes and Natural Killer (NK) cells will be
significantly enhanced. This leads to more effective antibody-dependent cellular cytotoxicity
(ADCC) and phagocytosis (ADCP). Thus, the capacity of an antibody to trigger the death of
targeted cells is improved.

With the GlycoOpitimize™ platform, Creative Biolabs has developed various glycoengineering
services, including Non- or Simplified-Glycosylated Antibodies Service, Low- or
Non-Fucosylated Antibodies Service, Over- or De-Sialylated Antibodies Service, In Vitro Enzymic
and Chemo-Enzymatic Antibody Glycosylation Remodeling Service, Antibody Glycan Analysis
Service, etc.

“Our scientists are fully confident to provide efficient and economically feasible antibody
glycoengineering solutions”, introduced Dr. Monika, scientific officer of Creative Biolabs. “We
are also able to produce glyco-optimized antibodies in a range of cell lines both for research
quantities and in large scale.”

About Creative Biolabs

Creative Biolabs is a biotech service provider of therapeutic antibody discovery and

manufacturing, offering high quality service to customers in academia and industry fields all over
the world, including chimeric antigen receptor (CAR) products, conjugate antibodies, therapeutic
antibodies, single domain antibodies, bispecific antibodies, etc.

https://www.biospace.com/